TW201613592A - Glucose metabolism ameliorating agent - Google Patents

Glucose metabolism ameliorating agent

Info

Publication number
TW201613592A
TW201613592A TW104119424A TW104119424A TW201613592A TW 201613592 A TW201613592 A TW 201613592A TW 104119424 A TW104119424 A TW 104119424A TW 104119424 A TW104119424 A TW 104119424A TW 201613592 A TW201613592 A TW 201613592A
Authority
TW
Taiwan
Prior art keywords
glucose metabolism
metabolism ameliorating
ameliorating agent
glp
exceptional
Prior art date
Application number
TW104119424A
Other languages
English (en)
Inventor
Toshihide Suzuki
Kenji Yamamoto
Yoshinori Beppu
Hiroshi Watanabe
Original Assignee
Suntory Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Holdings Ltd filed Critical Suntory Holdings Ltd
Publication of TW201613592A publication Critical patent/TW201613592A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
TW104119424A 2014-06-20 2015-06-16 Glucose metabolism ameliorating agent TW201613592A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2014127769 2014-06-20

Publications (1)

Publication Number Publication Date
TW201613592A true TW201613592A (en) 2016-04-16

Family

ID=54935434

Family Applications (1)

Application Number Title Priority Date Filing Date
TW104119424A TW201613592A (en) 2014-06-20 2015-06-16 Glucose metabolism ameliorating agent

Country Status (10)

Country Link
US (1) US20170143701A1 (zh)
EP (1) EP3158996A1 (zh)
JP (1) JP6513659B2 (zh)
KR (1) KR20170020459A (zh)
CN (1) CN106456633A (zh)
AU (1) AU2015278036A1 (zh)
HK (1) HK1231388A1 (zh)
SG (1) SG11201610280PA (zh)
TW (1) TW201613592A (zh)
WO (1) WO2015194447A1 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014279129B2 (en) 2013-06-10 2018-07-12 Suntory Holdings Limited Plant extract containing diketopiperazine and method for producing same
WO2017018404A1 (ja) * 2015-07-27 2017-02-02 サントリーホールディングス株式会社 環状ジペプチド及び甘味料を含有する組成物
JP6369951B2 (ja) * 2015-08-26 2018-08-08 三井農林株式会社 ジペプチジルペプチダーゼ−ｉｖ阻害剤
US20190328010A1 (en) * 2016-12-21 2019-10-31 Suntory Holdings Limited Food and beverages containing cyclo(alanyl-serine) and ethanol and/or propylene glycol
KR200486717Y1 (ko) 2017-10-03 2018-06-22 석민호 모자를 가지는 상의
CN109239346B (zh) * 2018-10-31 2019-10-11 中国药科大学 一组代谢标志物在代谢综合征早期诊断方面的应用
CN109824757B (zh) * 2019-02-15 2020-12-25 山东蓬勃生物科技有限公司 一种环（异亮-异亮）二肽、其制备方法及其应用
AU2022220528A1 (en) * 2021-02-12 2023-08-31 Neuren Pharmaceuticals Limited Treatments of prader-willi syndrome

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03220179A (ja) * 1990-01-23 1991-09-27 Chisso Corp 新規な環状ジペプチド誘導体及びその製造法
JP3634891B2 (ja) * 1995-04-06 2005-03-30 株式会社海洋バイオテクノロジー研究所 キチナーゼ阻害物質
JPH1084911A (ja) * 1996-07-25 1998-04-07 Ota Isan:Kk 血糖上昇抑制用食品素材
US5834032A (en) * 1997-08-11 1998-11-10 Song; Moon K. Compositions and methods for treating diabetes
CN101279094A (zh) * 2003-05-15 2008-10-08 Dmi生物科学公司 T-细胞介导的疾病的治疗
EP2039366A4 (en) * 2006-04-21 2010-01-06 Meiji Seika Kaisha COMPOSITION CONTAINING PEPTIDE AS ACTIVE INGREDIENT
MY178405A (en) * 2009-12-25 2020-10-12 Suntory Holdings Ltd Learning motivation improvers
DE102010029399A1 (de) * 2010-05-27 2011-12-01 Evonik Degussa Gmbh Cyclische Dipeptide als Futtermitteladditive
JP2015157765A (ja) * 2012-06-11 2015-09-03 日本恒順株式会社 香酢精製物の製造方法
JP5456876B1 (ja) * 2012-12-25 2014-04-02 ゼライス株式会社 環状ジペプチドの製造方法

Also Published As

Publication number Publication date
AU2015278036A1 (en) 2017-01-05
JP6513659B2 (ja) 2019-05-15
EP3158996A1 (en) 2017-04-26
US20170143701A1 (en) 2017-05-25
HK1231388A1 (zh) 2017-12-22
JPWO2015194447A1 (ja) 2017-04-20
SG11201610280PA (en) 2017-01-27
WO2015194447A1 (ja) 2015-12-23
KR20170020459A (ko) 2017-02-22
CN106456633A (zh) 2017-02-22

Similar Documents

Publication Publication Date Title
TW201613592A (en) Glucose metabolism ameliorating agent
PH12017502298B1 (en) Antibacterial compounds
MX2015009106A (es) Composiciones de solución sólida y su uso en el tratamiento del dolor intenso.
MY187540A (en) Compounds active towards bromodomains
MX2017007392A (es) Tratamiento de convulsiones con fosfatasa alcalina recombinante.
PH12019501010A1 (en) Arginase inhibitor combination therapies
MX2017005134A (es) Tratamiento del cáncer con inmunoestimuladores.
MX363896B (es) Combinación de un antagonista de cxcr4y y citarabina para el uso en el tratamiento de leucemia mieloide.
PH12019501722A1 (en) Compositions and methods for promoting hair growth with mpc1 inhibitors
NZ733670A (en) Insulin glargine/lixisenatide fixed ratio formulation
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
MX2017016096A (es) Agente antihipertensivo.
MX2017012596A (es) Una composicion farmaceutica y el uso de la misma.
PH12018502161A1 (en) Methods of treatment for cholestatic and fibrotic diseases
MX359029B (es) Procedimiento para el tratamiento de enfermedades relacionadas con el factor inducible por hipoxia (hif) -.
AU201613321S (en) A Compliance Monitor for a Medicament Inhaler
MX2019000677A (es) Células miméticas de células b.
BR112017014552A2 (pt) ?análogo de calcitonina, e, método para produzir uma diminuição nos triglicerídeos no fígado/redução de acúmulo de gordura no fígado?
MX2017009313A (es) Formulaciones intravenosas de baclofeno y metodos de tratamiento.
MX2020007270A (es) Formulacion parenteral que comprende siponimod.
PH12017501979A1 (en) Pharmaceutical compound
GEP20207145B (en) Combination of trazodone and gabapentin for the treatmen
MX2019013207A (es) Metodos y composiciones para tratar la endometriosis y sintomas asociados a la endometriosis.
WO2018132160A3 (en) Methods of treating or preventing type 1 diabetes
AU367396S (en) A compliance monitor for a medicament inhaler